<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Studies evaluating the role of lead in CKD</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Studies evaluating the role of lead in CKD</h1>
<div class="graphic"><div class="figure"><div class="ttl">Studies evaluating the role of lead in CKD</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1">Reference </td> <td class="subtitle1">N </td> <td class="subtitle1">Baseline mean (SD) blood lead (microgram/dL) </td> <td class="subtitle1">Baseline mean (SD) chelatable lead (microgram/72 hours) </td> <td class="subtitle1">Baseline mean (SD) eGFR (mL/min/1.73 m<sup>2</sup>) </td> <td class="subtitle1">Follow-up (years) </td> <td class="subtitle1">Decline in eGFR per 1 SD higher lead dose at baseline per year </td> <td class="subtitle1">Comments </td> </tr> <tr> <td>[1]</td> <td>202</td> <td>5.3 (2.9)</td> <td>104.5 (106.3)</td> <td>41.6 (14.4)</td> <td>two</td> <td>0.16</td> <td>Largest study to date</td> </tr> <tr> <td>[2]</td> <td>121</td> <td>4.2 (2.2)</td> <td>99.1 (83.4)</td> <td>36.0 (9.8)</td> <td>four</td> <td> <p>2.7 (chelatable)</p> <p>2.2 (blood lead)</p> </td> <td>Longest follow-up; 1 microgram/dL higher blood lead, at baseline, associated with 4.0 mL/min/1.73 m<sup>2</sup> reduction in eGFR over four years</td> </tr> <tr> <td>[3]</td> <td>87</td> <td>6.5 (3.4)</td> <td>108.5 (53.8)</td> <td>35.1 (9.0)</td> <td>one</td> <td>3.87</td> <td>Type II diabetics with nephropathy</td> </tr> <tr> <td>[4]</td> <td>108</td> <td>2.9 (1.4)*</td> <td>40.2 (21.2) (all &lt;80)</td> <td>47.6 (9.8)</td> <td>two</td> <td>1.1</td> <td>Lowest lead exposed CKD patients</td> </tr> <tr> <td>[5]</td> <td>434 participants with ESRD </td> <td>Categories based on highest prior blood lead level in lead surveillance program: &lt;5, 5 to &lt;25, 25 to &lt;40, 40 to &lt;50, ≥50 mcg/dL</td> <td>N/A </td> <td>ESRD based on inclusion in USRDS </td> <td>Median of 2.7 </td> <td>No association between highest blood lead levels measured before and survival after ESRD diagnosis </td> <td>Occupational lead exposure; ESRD</td> </tr> <tr> <td>[6] </td> <td>801</td> <td>Occupational exposure based on expert rating method using job history </td> <td>N/A </td> <td>Mean eGFR &lt;20 mL/min/1.73 m<sup>2</sup> </td> <td>Mean of 2.5 </td> <td>Progression did not differ by occupational lead exposures </td> <td>ESRD; occupational exposure in 70 participants </td> </tr> </tbody></table></div><div class="graphic_footnotes">SD: standard deviation; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease; ESRD: end-stage renal disease; USRDS: United States Renal Data System.<br/>* Notably, mean blood lead level in this study was below that observed in a large general population study of 50 to 70 year olds in Baltimore, MD<sup>[7]</sup>.</div><div class="graphic_reference">References:<br/><ol>
<li>Lin JL, Lin-Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 2003; 348:277.</li>
<li>Yu CC, Lin JL, Lin-Tan DT. Environmental exposure to lead and progression of chronic renal diseases: a four-year prospective longitudinal study. J Am Soc Nephrol 2004; 15:1016.</li>
<li>Lin JL, Lin-Tan DT, Yu CC, et al. Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes. Kidney Int 2006; 69:2049.</li>
<li>Lin JL, Lin-Tan DT, Li YJ, et al. Low-level environmental exposure to lead and progressive chronic kidney diseases. Am J Med 2006; 119:707.</li>
<li>Chowdhury R, Mukhopadhyay A, McClellan W, et al. Survival patterns of lead-exposed workers with end-stage renal disease from Adult Blood Plead Epidemiology and Surveillance program. Am J Med Sci 2015; 349:222.</li>
<li>Evans M. Fored CM, Nise G, et al. Occupational lead exposure and severe CKD: A population-based case-control and prospective observational cohort study in Sweden. Am J Kidney Dis 2010; 55:497.</li>
<li>Martin D, Glass TA, Bandeen-Roche K, et al. Association of blood lead and tibia lead with blood pressure and hypertension in a community sample of older adults. Am J Epidemiol 2006; 163:467.</li></ol></div><div id="graphicVersion">Graphic 72174 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
